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30, 2008 within a large nationwide network of outpatient oncology clinics were 
studied using US Oncology’s iKnowMed EMR. Costs included only those incurred 
within the network of outpatient oncology clinics and were derived using Medicare 
reimbursement rates. Patients were matched across regimens on key confounding 
factors at initiation of treatment: age, stage at diagnosis, ECOG performance status, 
and comorbidity index. A variable N:M matching ratio was used. Patients were fol-
lowed through June 30, 2009. A 95% conﬁdence intervals were estimated by boot-
strapping (2500 samples) the within-cell differences in cost and time to progression 
(TTP) of matched patients. RESULTS: A total of 1194 patients were identiﬁed: 48 
received P/P, 279 received C/P + B, and 867 received C/P. We found that P/P exhibited 
dominance vs. C/P + B, with higher effectiveness (mean difference in TTP = 1.7 
months; CI = 1.1- 2.3 months) and lower cost (mean cost difference = −$22,890; CI 
= $−25,445–$−20,335). Compared to C/P, P/P had higher effectiveness (mean differ-
ence in TTP = 2.0 months; CI = 1.7- 2.4 months) but also higher costs (mean cost 
difference = $12,603; CI = $11,579–$13,667) with an incremental cost effectiveness 
of $6,335/progression-free month (CI = 5,432–7,404). CONCLUSIONS: This study 
suggests that P/P may be a cost-effective 1st line NSCLC treatment in the outpatient 
community setting. Costs differences were substantial by regimen while differences in 
TTP were relatively small from a clinical perspective. While this preliminary study 
utilized conservative analytic methods and controlled for several key confounding 
factors, future large studies should attempt to further address selection bias and 
residual confounding.
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OBJECTIVES: To estimate health care utilization and costs for patients with incident 
metastatic squamous cell carcinoma of head and neck (mSCCHN). METHODS: 
Incident mSCCHN patients between 1993 and 2005 were identiﬁed in the SEER-
Medicare database using ICD-O codes for primary site and histology with a “distant” 
tumor in the SEER staging variable. Individuals 65 years or older at the time of 
diagnosis, with at least 12 months of data preceding initial diagnosis were included. 
The index date was deﬁned as the date of diagnosis; subjects were followed from 30 
days prior to the index date until death or the end of Medicare claims data (December 
31, 2007), whichever occurred ﬁrst. Chemotherapy use was identiﬁed using HCPCS 
codes. Resource use and health care costs were estimated using the person-years 
approach to account for patients having different lengths of follow-up. RESULTS: A 
total of 1420 subjects with mSCCHN were included in this analysis. Mean age was 
74 (SD 6.7) years and 70% were males. Mean Charlson comorbidity score without 
malignancy was 1.4 (SD 1.6) and mean duration of follow-up was 30 months (SD 
33). Forty-eight percent of patients received chemotherapy. Carboplatin (18%) was 
the most commonly used agent followed by paclitaxel (13%) and cisplatin (11%). 
The mean number of visits per patient per year was 9.7 (SD 10.7) for outpatient care 
and 2.9 (SD 3.7) for inpatient care. Average annual inpatient days per patient were 
31.4 days (SD 51.1). About 40% of the patients received hospice care. Mean total 
annual health care costs per patient were $155,307, cost of outpatient care constituted 
51% and inpatient care 34%. CONCLUSIONS: Inpatient and outpatient costs are 
the key drivers of total health care costs for patients with mSCCHN.
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OBJECTIVES: Trastuzumab (Tras) in combination with chemotherapy is the current 
treatment standard in patients with early and metastatic breast cancer (BC) who are 
HER2 positive (HER2+). Any regimen under development will have to be compared 
to Tras both in pivotal clinical trials and during economic assessment. This study raises 
important policy questions by estimating the feasibility of demonstrating cost-effec-
tiveness (CE) against conventional UK NICE thresholds (£ 20–30,000/QALY gained) 
for new regimens developed in different lines of treatment for HER2+ BC and incen-
tives for development where rigid thresholds are applied. METHODS: Three CE 
models were developed using rates of disease progression, survival and efﬁcacy data 
from 3 Tras clinical trials: HERA for adjuvant, M77001 for 1st-line metastatic and 
GBG-26 for 2nd-line metastatic BC. Isometrics curves were generated for each model 
whereby each point on the curve corresponded to where the progression-free & overall 
survival hazard ratios and increase in total costs for the new treatment versus Tras 
was estimated to result in an ICER of £ 30’000/QALY. Costs and utility values were 
based on published literature from the UK-NHS perspective. RESULTS: Assuming a 
5-year duration of efﬁcacy in early BC (PFS hazard ratio of 0.75), the model estimated 
that a new treatment could be considered cost-effective with medication acquisition 
costs 81% above Tras. In the metastatic setting (1st and 2nd-line), similar incremental 
improvements in efﬁcacy, for the OS and PFS hazard ratios over 5 years, suggests that 
a new regimen could not have medication acquisition costs more than 6–7% above 
Tras. CONCLUSIONS: Given current treatment costs of the background regimen, it 
is unlikely that any new combination regimen will be cost-effective using UK thresh-
olds. Results were not sensitive to the magnitude of the incremental survival beneﬁt 
due to the high correlation between treatment beneﬁt, treatment duration (until cancer 
progression), and overall treatment costs.
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OBJECTIVES: ED use for non-emergencies contributes to crowding, increased health 
care costs, and, potentially, poor clinical outcomes. Efforts to decrease inappropriate 
ED use have focused on insured individuals. The purpose of this retrospective cohort 
study was to characterize frequent ED use among un- and underinsured individuals 
in central Texas. METHODS: Data were obtained from the ICare system, which 
includes information for > 800,000 individuals and > 5 million encounters within 24 
Central Texas health care providers who arrange for or provide care for uninsured or 
underinsured individuals. Persons who received care from an ICare-participating orga-
nization during calendar year 2007 were included in these analyses. Frequent ED use 
was deﬁned as at least 6 ED visits within either a calendar quarter or any contiguous 
three-month period. Linear regression was used to estimate the relation between 
patient characteristics and total ED visits among frequent users. RESULTS: There 
were 216,364 ED visits in 2007; 128,538 individuals had at least 1 ED visit and 0.7% 
(n = 892) were considered frequent ED users. Frequent users were mainly female 
(55.6%), and Caucasian (55.8%). Hispanics and African-Americans accounted for 
14.2% and 17.3% of frequent users, respectively. The regression model accounted for 
12.1% of variability in the outcome. Total clinic visits (beta = 0.05, p 0.037, 95% CI 
0.003–0.094), inpatient admissions (beta = 1.35, p < 0.001, 95% CI 0.976–1.716) 
and having any mental health diagnosis in any ED visit (beta = 3.278, p < 0.001. 95% 
CI 2.060–4.496) were positively and statistically signiﬁcantly associated with the 
number of ED visits among frequent users, after adjusting for age, sex, and race. 
CONCLUSIONS: In 2007, frequent users accounted for < 1% of ED users, and 5.4% 
of total ED use. A study of these frequent users may help identify opportunities for 
intervention to help underlying causes for these frequent visits.
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OBJECTIVES: To compare the pharmaceutical STA guidance advice of Haute Autorité 
de santé (HAS) which appraises clinical efﬁcacy/safety against the Scottish Medicines 
Consortium (SMC) in which appraisal includes both clinical and cost-effectiveness. 
METHODS: All English translated advice were downloaded from the HAS website 
resulting in 78 transparency committee opinions for between 2005 and 2009. These 
were matched with SMC advice, resulting in 39 matched drugs. A comparison between 
drug advice, the clinical evidence through identiﬁcation of trials on the CENTRAL 
database of the Cochrane library and a statistical analysis was performed on improve-
ment in medical beneﬁt (ASMR) supplied by HAS and the cost-utility estimates (CQG) 
of the SMC. RESULTS: The HAS and SMC had the same advice in 14/39 (36%) of the 
drug comparisons. The average number of trials included were 2 trials in HAS advice 
and 1.8 trials in SMC advice with more comprehensive detail on the efﬁcacy in HAS 
advice. Each matched comparison had at least one common trial and 30% of guidance 
included different additional trials. The correlation between the medical improvement 
provided by HAS and the SMC CQG were analysed and show that for those treatments 
considered cost saving by the SMC the ASMR was on average 4.6. The CQG for 
£0-£10,000 had an average ASMR; 3.6, £10,000-£20,000; 2.8, £20,000-£30,000; 3.1, 
and £30,000+; 3.4, showing little correlation between ASMR and CQG. CONCLU-
SIONS: The differences in guidance advice reﬂect the countries different HTA pro-
cesses, interpretation of clinical efﬁcacy and approaches to economics. HAS advice 
provided more detailed information on the clinical efﬁcacy in comparison to SMC for 
these drugs. The SMC presented formal analysis of cost-effectiveness in comparison to 
France where economic issues are considered by the economic committee and not 
reported. The transparency committee implicitly uses economics as the choice of ASMR 
inﬂuences pricing decisions and the cost-effectiveness of treatments.
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OBJECTIVES: Prices of recently launched monoclonal antibodies are high and their 
accessibility differs across Europe. Trastuzumab (TRZ) was recommended by payers 
for early and advanced breast cancer (BC) in Europe, with differences in the process 
and timelines of recommendations. Cetuximab (CTX) for metastatic colorectal cancer 
